JP2012506450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506450A5 JP2012506450A5 JP2011533313A JP2011533313A JP2012506450A5 JP 2012506450 A5 JP2012506450 A5 JP 2012506450A5 JP 2011533313 A JP2011533313 A JP 2011533313A JP 2011533313 A JP2011533313 A JP 2011533313A JP 2012506450 A5 JP2012506450 A5 JP 2012506450A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- eye
- damage
- composition according
- retinal ganglion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19699508P | 2008-10-22 | 2008-10-22 | |
| US61/196,995 | 2008-10-22 | ||
| US19893108P | 2008-11-11 | 2008-11-11 | |
| US61/198,931 | 2008-11-11 | ||
| IL2009000179 | 2009-02-15 | ||
| ILPCT/IL2009/000179 | 2009-02-15 | ||
| PCT/US2009/061570 WO2010048352A2 (en) | 2008-10-22 | 2009-10-22 | Methods for treating eye disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506450A JP2012506450A (ja) | 2012-03-15 |
| JP2012506450A5 true JP2012506450A5 (https=) | 2013-04-25 |
| JP5592892B2 JP5592892B2 (ja) | 2014-09-17 |
Family
ID=54839547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533313A Active JP5592892B2 (ja) | 2008-10-22 | 2009-10-22 | 眼障害の治療方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US8765931B2 (https=) |
| EP (1) | EP2350279B1 (https=) |
| JP (1) | JP5592892B2 (https=) |
| KR (1) | KR101672563B1 (https=) |
| CN (3) | CN102994500B (https=) |
| AU (1) | AU2009308380B2 (https=) |
| BR (1) | BRPI0919683A2 (https=) |
| CA (2) | CA2962219C (https=) |
| DK (1) | DK2350279T3 (https=) |
| EA (1) | EA022418B1 (https=) |
| ES (1) | ES2563984T3 (https=) |
| HU (1) | HUE026751T2 (https=) |
| IL (1) | IL212986A (https=) |
| NZ (1) | NZ591391A (https=) |
| PL (1) | PL2350279T3 (https=) |
| SI (1) | SI2350279T1 (https=) |
| WO (1) | WO2010048352A2 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009147684A2 (en) * | 2008-06-06 | 2009-12-10 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| CA2962219C (en) * | 2008-10-22 | 2020-08-25 | Quark Pharmaceuticals, Inc. | Methods for treating eye disorders |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| CN104313027B (zh) * | 2009-08-11 | 2018-11-20 | 库尔纳公司 | 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病 |
| AU2010324658A1 (en) | 2009-11-26 | 2012-05-03 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
| WO2012006083A2 (en) * | 2010-07-09 | 2012-01-12 | University Of Florida Research Foundation, Inc. | Targeted receptor-mediated sirna |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| AU2012332517B9 (en) | 2011-11-03 | 2017-08-10 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
| US20140323549A1 (en) * | 2011-11-08 | 2014-10-30 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
| EP2800812A1 (en) | 2012-01-04 | 2014-11-12 | Quark Pharmaceuticals, Inc. | Double-stranded rna compounds to casp2 and uses thereof |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| ES2704855T3 (es) | 2012-09-12 | 2019-03-20 | Quark Pharmaceuticals Inc | Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas |
| EP2895607B1 (en) | 2012-09-12 | 2021-05-05 | Quark Pharmaceuticals, Inc. | Double-stranded oligonucleotide molecules to ddit4 and methods of use thereof |
| CN104661682B (zh) * | 2012-09-27 | 2018-05-11 | 千寿制药株式会社 | 水性液剂 |
| EP2970972B1 (en) * | 2013-03-11 | 2018-08-15 | Fondazione Telethon | Mir-204 and mir-211 and uses thereof |
| IL288931B2 (en) | 2013-03-14 | 2025-05-01 | Alnylam Pharmaceuticals Inc | Compositions comprising a complementary portion of C5 IRNA and methods of using them |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| US20160319278A1 (en) | 2015-04-03 | 2016-11-03 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| US10752896B2 (en) | 2015-09-08 | 2020-08-25 | Sylentis Sau | siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene |
| EP3487507A4 (en) * | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| EP3512948A4 (en) * | 2016-09-09 | 2020-05-13 | Cornell University | ADMINISTRATION OF NUCLEIC ACIDS, PROTEINS AND SMALL MOLECULES IN GLASS-LIKE VESICULAR BODIES |
| US20180092776A1 (en) | 2016-09-30 | 2018-04-05 | Sara Heikali | Method and device for treating and managing diseased ocular tissue |
| RU2766353C2 (ru) * | 2016-11-02 | 2022-03-15 | Фридрих Мишер Инститьют Фор Байомедикал Рисерч | Synp198, промотор для специфической экспрессии генов в ганглионарных клетках сетчатки, избирательных в отношении направления |
| RU2633349C1 (ru) * | 2016-11-24 | 2017-10-11 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| RU2643579C1 (ru) * | 2017-03-29 | 2018-02-02 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемической нейропатии зрительного нерва карбамилированным дарбэпоэтином в эксперименте |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
| CN110604811B (zh) * | 2018-06-14 | 2023-01-31 | 陕西慧康生物科技有限责任公司 | 含有重组人溶菌酶和重组人表皮生长因子的人工泪液 |
| CN113528510A (zh) | 2018-06-29 | 2021-10-22 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| SG11202101032VA (en) * | 2018-08-20 | 2021-02-25 | Wuhan Neurophth Biotechnology Ltd Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| AU2019343188A1 (en) | 2018-09-21 | 2021-05-20 | Aufbau Medical Innovations Limited | Compositions and methods for glaucoma |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| EP3914205A4 (en) * | 2019-01-22 | 2022-09-14 | The Board of Trustees of the Leland Stanford Junior University | SILICONE OIL INDUCED HYPERPRESSURE AND GLAUCOMA MODEL |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| WO2021081026A1 (en) | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| JP2021080253A (ja) * | 2019-11-19 | 2021-05-27 | ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． | 眼を治療するための組成物及び方法 |
| US11969451B2 (en) | 2019-11-19 | 2024-04-30 | Johnson & Johnson Surgical Vision, Inc. | Compositions and methods for treating the eye |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| TWI819268B (zh) * | 2020-01-16 | 2023-10-21 | 詹姆斯 Ｗ 希爾 | 藉由基因轉導改變眼睛顏色 |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| CN112063624A (zh) * | 2020-09-19 | 2020-12-11 | 湖南中医药大学 | 一种抑制caspase 1基因表达的siRNA分子及其应用 |
| WO2022223515A2 (en) | 2021-04-19 | 2022-10-27 | Novo Nordisk A/S | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| WO2023014654A2 (en) * | 2021-08-02 | 2023-02-09 | University Of Massachusetts | Oligonucleotides for htt-1a modulation |
| CN118302525A (zh) | 2021-10-29 | 2024-07-05 | 阿尔尼拉姆医药品有限公司 | 补体因子B（CFB）iRNA组合物及其使用方法 |
| CN116548384B (zh) * | 2023-04-12 | 2026-02-13 | 电子科技大学 | 一种青光眼干预疾病模型的构建方法 |
| EP4560019A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| EP4560020A1 (en) | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251666B1 (en) * | 1997-03-31 | 2001-06-26 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid catalysts comprising L-nucleotide analogs |
| AU2001289068A1 (en) * | 2000-09-20 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 2 expression |
| US20060217331A1 (en) * | 2001-05-18 | 2006-09-28 | Sirna Therapeutics, Inc. | Chemically modified double stranded nucleic acid molecules that mediate RNA interference |
| US20050282188A1 (en) * | 2001-05-18 | 2005-12-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| US20030157030A1 (en) * | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
| DE60310944T3 (de) * | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| AU2004217437B2 (en) * | 2003-03-05 | 2009-11-19 | Senesco Technologies, Inc. | Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
| FR2855054B1 (fr) * | 2003-05-22 | 2005-07-08 | Theraptosis | Moyens pour bloquer ou retarder une mort cellulaire in vitro |
| EP1626732B1 (en) * | 2003-05-22 | 2013-04-03 | CHIESI FARMACEUTICI S.p.A. | Means for preventing and treating cellular death and their biological applications |
| EP2319925B1 (en) * | 2004-08-16 | 2018-07-25 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of RTP801 |
| TW200639252A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular hypertension targets |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US20100292301A1 (en) | 2007-02-28 | 2010-11-18 | Elena Feinstein | Novel sirna structures |
| RU2487716C2 (ru) | 2007-10-03 | 2013-07-20 | Кварк Фармасьютикалс, Инк. | Новые структуры малых интерферирующих рнк (sirna) |
| CA2962219C (en) * | 2008-10-22 | 2020-08-25 | Quark Pharmaceuticals, Inc. | Methods for treating eye disorders |
-
2009
- 2009-10-22 CA CA2962219A patent/CA2962219C/en active Active
- 2009-10-22 CN CN201210278029.7A patent/CN102994500B/zh active Active
- 2009-10-22 AU AU2009308380A patent/AU2009308380B2/en active Active
- 2009-10-22 DK DK09748890.2T patent/DK2350279T3/en active
- 2009-10-22 ES ES09748890.2T patent/ES2563984T3/es active Active
- 2009-10-22 US US13/062,161 patent/US8765931B2/en active Active
- 2009-10-22 HU HUE09748890A patent/HUE026751T2/en unknown
- 2009-10-22 JP JP2011533313A patent/JP5592892B2/ja active Active
- 2009-10-22 EP EP09748890.2A patent/EP2350279B1/en active Active
- 2009-10-22 CA CA2738957A patent/CA2738957A1/en not_active Abandoned
- 2009-10-22 KR KR1020117009590A patent/KR101672563B1/ko active Active
- 2009-10-22 PL PL09748890T patent/PL2350279T3/pl unknown
- 2009-10-22 NZ NZ59139109A patent/NZ591391A/xx unknown
- 2009-10-22 WO PCT/US2009/061570 patent/WO2010048352A2/en not_active Ceased
- 2009-10-22 BR BRPI0919683-8A patent/BRPI0919683A2/pt not_active Application Discontinuation
- 2009-10-22 EA EA201170551A patent/EA022418B1/ru not_active IP Right Cessation
- 2009-10-22 CN CN201510090523.4A patent/CN104857526B/zh active Active
- 2009-10-22 CN CN2009801517703A patent/CN102449151A/zh active Pending
- 2009-10-22 SI SI200931373T patent/SI2350279T1/sl unknown
-
2011
- 2011-03-21 IL IL212986A patent/IL212986A/en active IP Right Grant
-
2014
- 2014-03-17 US US14/217,079 patent/US9121020B2/en active Active
-
2015
- 2015-08-27 US US14/837,366 patent/US9701961B2/en active Active
-
2017
- 2017-07-10 US US15/645,751 patent/US20170306329A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506450A5 (https=) | ||
| Skeie et al. | Mitophagy: an emerging target in ocular pathology | |
| JP5592892B2 (ja) | 眼障害の治療方法 | |
| ES2462416T3 (es) | Producto farmacéutico que contiene un inhibidor de la expresión de HIF-1 alfa y HIF-2 alfa | |
| JP6742362B2 (ja) | 眼の状態を処置および／または防止するためのｓｉＲＮＡならびに方法および組成物におけるそれらの使用 | |
| Supe et al. | Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy | |
| CA2918858A1 (en) | Carnitine palmitoyltransferase 1 inhibitors for inhibition of pathological angiogenesis | |
| EP2994197B1 (en) | Pharmaceutical combination of an nsaid and atropine | |
| US9561234B2 (en) | Methods for treating diseases of the retina | |
| US10752896B2 (en) | siRNA and their use in methods and compositions for inhibiting the expression of the NRARP gene | |
| WO2024230934A1 (en) | Therapeutic nucleic acid for the treatment of ophthalmic diseases | |
| AU2012389270B2 (en) | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| US10011837B2 (en) | SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| CN107530380B (zh) | 用于治疗眼疾的台湾蜂胶萃取物 | |
| AU2013206951A1 (en) | Double-stranded RNA compounds to CASP2 and uses thereof | |
| WO2017042239A1 (en) | siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene | |
| US20240035033A1 (en) | Prevention and treatment of age-related macular degeneration through suppression of cathepsin s expression | |
| Frößl | Evaluation of brimonidine loaded DNA-nanoparticles | |
| Yang et al. | Quercetin ameliorates SIRT1-mediated oxidative stress and inflammation to attenuate ciliary muscle remodeling in experimental myopia | |
| WO2026078034A1 (en) | Sitagliptin for use in retinal diseases with neovascularization | |
| CN121175028A (zh) | Oca2调节剂、其组合物及其用途 | |
| US20160038521A1 (en) | Therapeutic methods | |
| WO2004096146A2 (en) | Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage | |
| HK1211983B (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions | |
| JP2017200928A (ja) | ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用 |